Document:

EX-10.x

 Exhibit 10x 
 *Confidential Treatment Requested 
  

 
 AMENDED AND RESTATED 

TERRITORY A PRODUCT KNOW-HOW LICENSE AGREEMENT 
 among 
 SANOFI 

BRISTOL-MYERS SQUIBB COMPANY 
 and 
 SANOFI PHARMA BRISTOL-MYERS SQUIBB 

dated as of January 1, 2013 
  

 
 *CONFIDENTIAL TREATMENT REQUESTED.
CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 TABLE OF CONTENTS 

 

							
		 	ARTICLE 1	  			
		 	DEFINITIONS	  			
			
	 1.1
	 	Defined Terms	  	 	2	  
	 1.2
	 	Additional Defined Terms	  	 	4	  
			
		 	ARTICLE 2	  			
		 	GRANT OF LICENSE	  			
			
	 2.1
	 	License Grant	  	 	5	  
	 2.2
	 	No Transfer	  	 	5	  
	 2.3
	 	No Implicit Rights	  	 	5	  
	 2.4
	 	Goodwill	  	 	6	  
	 2.5
	 	Corporate Name Authorization	  	 	6	  
	 2.6
	 	Location-Gérance	  	 	6	  
			
		 	ARTICLE 3	  			
		 	SUB-LICENSE	  			
			
	 3.1
	 	General Sub-License	  	 	6	  
	 3.2
	 	Termination of Sub-License	  	 	6	  
			
		 	ARTICLE 4	  			
		 	CONSIDERATION	  			
			
	 4.1
	 	Development Royalty	  	 	6	  
	 4.2
	 	Payment	  	 	6	  
	 4.3
	 	Method of Payment	  	 	7	  
	 4.4
	 	Records	  	 	7	  
	 4.5
	 	Taxes	  	 	7	  
			
		 	ARTICLE 5	  			
		 	TERM; TERMINATION	  			
			
	 5.1
	 	Term; Termination	  	 	7	  
	 5.2
	 	Consequences of Termination	  	 	8	  
			
		 	ARTICLE 6	  			
		 	CONFIDENTIALITY	  			
			
		 	ARTICLE 7	  			
		 	MISCELLANEOUS	  			
			
	 7.1
	 	Notices	  	 	9	  
	 7.2
	 	Governing Law	  	 	11	  
	 7.3
	 	Dispute Resolution	  	 	11	  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 i 

							
	 7.4
	 	Specific Performance	  	 	11	  
	 7.5
	 	No Third Party Beneficiaries	  	 	12	  
	 7.6
	 	Assignment	  	 	12	  
	 7.7
	 	Severability	  	 	12	  
	 7.8
	 	Waivers and Amendments	  	 	12	  
	 7.9
	 	Headings	  	 	13	  
	 7.10
	 	Entire Agreement	  	 	13	  
	 7.11
	 	No Partnership or Joint Venture	  	 	13	  
	 7.12
	 	Governing Language	  	 	13	  
	 7.13
	 	Counterparts	  	 	13	  
	 7.14
	 	Force Majeure	  	 	13	  
	 7.15
	 	Definitive Agreement	  	 	14	  

 SCHEDULES 
 SCHEDULE 1A       TERRITORY A 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 ii 

 This AMENDED AND RESTATED PRODUCT KNOW-HOW LICENSE AGREEMENT (this
“Agreement”) dated as of January 1, 2013 is hereby made by and among: 
 Sanofi, a
société anonyme organized and existing under the laws of the French Republic (“Sanofi”); 

Bristol-Myers Squibb Company, a corporation organized and existing under the laws of the State of Delaware, United States of America
(“BMS”); and 
 Sanofi Pharma Bristol-Myers Squibb, a société en nom collectif organized
and existing under the laws of the French Republic (the “SNC Partnership” and, together with Sanofi and BMS, the “Parties” and, individually, each a “Party”). 

W I T N E S S E T H: 
 WHEREAS, Sanofi previously discovered and patented two new chemical entities, one known as SR 47436 with the international non-proprietary name Irbesartan (“Irbesartan”) and one known as
SR 25990C with the international non-proprietary name Clopidogrel Hydrogenosulphate (“Clopidogrel”); 

WHEREAS, Sanofi, BMS and Sterling Winthrop Inc., a Delaware corporation (“Sterling”) entered into a Development
Agreement dated July 29, 1993 (the “Development Agreement”) for, among other things, the development of Irbesartan and Clopidogrel; 
 WHEREAS, pursuant to an Amended and Restated Asset Purchase Agreement dated as of September 30, 1994 among Eastman Kodak Company, Sanofi and Sterling, Sanofi acquired certain assets, and assumed
certain obligations, of the ethical pharmaceutical business of Sterling, including the rights and obligations of Sterling under the Development Agreement; 
 WHEREAS, Sanofi and BMS have entered into a Territory A Alliance Support Agreement dated as of January 1, 1997 (the “Alliance Support Agreement”) and have formed through their
indirect wholly owned subsidiaries the SNC Partnership for, among other things, the commercialization of the Products in Territory A (as such terms are defined in the Alliance Support Agreement); 

WHEREAS, Sanofi and the SNC Partnership have entered into an Irbesartan Intellectual Property License Agreement (the “Irbesartan
License Agreement”) and a Clopidogrel Intellectual Property License and Supply Agreement (the “Clopidogrel License Agreement”), each dated as of January 1, 1997, pursuant to which Sanofi granted the SNC Partnership a
license to use certain patents, trademarks and know-how that neither were developed with nor are owned by BMS, for the commercialization of the Products in Territory A; 
 WHEREAS, Sanofi and BMS have developed certain know-how under the Development Agreement for the commercialization of the Products in Territory A and, as a result, each has an undivided one-half direct
ownership interest in the Developed Know-How (as such term is defined herein); 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 WHEREAS, Sanofi, BMS and the SNC Partnership have entered into a Product Know-How License
Agreement (the “Original Agreement”), dated as of January 1, 1997, pursuant to which Sanofi and BMS granted to the SNC Partnership a license under the Developed Know-How for the commercialization of the Products in Territory A;

 WHEREAS, the SNC Partnership has been commercializing the Products in Territory A since that date; 

WHEREAS, pursuant to a Master Restructuring Agreement (the “Definitive Agreement”), dated as of September 27, 2012,
by and between Sanofi and BMS, Sanofi and BMS have agreed to simplify the overall governance, operating and financial principles of their alliance with respect to the Products; and 

WHEREAS, in connection with the transactions contemplated by the Definitive Agreement, Sanofi and BMS have agreed to, among other things,
(i) terminate the Alliance Support Agreement, (ii) amend and restate the Irbesartan License Agreement and the Clopidogrel License Agreement and (iii) amend and restate the Original Agreement on the terms set forth herein. 

NOW, THEREFORE, in consideration of the mutual covenants and the terms and conditions set forth herein, the Parties hereby agree to amend
and restate the Original Agreement as follows: 
 ARTICLE 1 

DEFINITIONS 
 1.1 Defined Terms. As used in this Agreement, the following terms shall have the following meanings: 
 “Affiliate”, when used with reference to any Person, means any other Person controlling, controlled by, or under common control with, such Person; provided, however, that, with respect to
Sanofi, the definition of Affiliate shall exclude L’Oréal, a société anonyme organized and existing under the laws of the French Republic. For the purposes of this definition, “control” shall refer to
(a) the possession, directly or indirectly, of the power to direct the management or policies of a Person or to veto any material decision relating to the management or policies of a Person, in each case whether through the ownership of voting
securities, by contract or otherwise; (b) the beneficial ownership, directly or indirectly, of securities (excluding general partnership interests) representing at least 50% of the voting power of all outstanding voting securities of a Person;
or (c) the beneficial ownership of at least 50% of the partnership interests of a general partnership. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 2 

 “Clopidogrel Product” means (i) a product with
the sole active ingredient Clopidogrel, in finished form, marketed under the trademarks Plavix® and Iscover® or any trademark that is confusingly similar to or that is a replacement for any such trademark, and (ii) a
product (an “Identified Clopi FDC”) which contains as the only active ingredients the combination of Clopidogrel with acetylsalicylic acid, in finished form, marketed under the trademarks DuoPlavin®, CoPlavix® and DuoCover® or any
trademark that is confusingly similar to or that is a replacement for any such trademark. For the avoidance of doubt, Clopidogrel Products shall exclude any Fixed Dose Combination Products. 

“Developed Know-How” means any and all technical data, information, material and other know-how that relate to the
formulation of the Products, including, without limitation, any analytical methodology, chemical, toxicological, pharmacological and clinical data, formulae, procedures, protocols, techniques and results of experimentation and testing, developed by
Sanofi and BMS under the Development Agreement. 
 “fixed dose combination” means a pharmaceutical dosage form
containing fixed doses of more than one active ingredient in which all active ingredients are present in a single tablet, capsule or other form and shall expressly exclude so-called “co-packaging” in which separate drugs in separate dosage
forms are sold in a single unit or bundle. 
 “Fixed Dose Combination Product” means a fixed dose combination
containing Clopidogrel or Irbesartan (other than the Identified Clopi FDCs and the Identified Irbe FDCs). 

“Governmental Authority” means any federal, state or local or any foreign or supranational government, governmental,
regulatory or administrative authority, agency or commission or any court, tribunal or judicial or arbitral body. 

“Identified Clopi FDC” has the meaning set forth in the definition of Clopidogrel Product. 

“Identified Irbe FDC” has the meaning set forth in the definition of Irbesartan Product. 

“IFRS Net Sales” means, with respect to a Product, net sales of Sanofi (or its Affiliates or their respective licensees
or sublicensees) as audited and reported in Euros by Sanofi (or its Affiliates or licensees) in accordance with International Financial Reporting Standards (“IFRS”), as IFRS may be modified from time to time. For the avoidance of
doubt: (a) IFRS Net Sales shall not include samples, compassionate use of the Products and the like; provided that revenue from Products sold to third parties for clinical trial purposes shall be included in IFRS Net Sales; and
(b) any Damages (as defined in the Definitive Agreement) paid by Sanofi pursuant to Article IX of the Definitive Agreement shall not be treated as a deduction for purposes of calculating IFRS Net Sales. In calculating IFRS Net Sales, the
Parties shall disregard any related Know-How, Discovery or other royalties paid to Sanofi after January 1, 2013 on Clopidogrel Products or Irbesartan Products. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 3 

 “Irbesartan Product” means: (a) a product with
the sole active ingredient Irbesartan, in finished form, marketed under the trademarks Aprovel®, Karvea® and Avapro® or any trademark that is confusingly similar to or that is a replacement for any such trademark; and (b) a product (an “Identified Irbe FDC”)
which contains as the only active ingredients the combination of Irbesartan with Hydrochlorothiazide, in finished form, marketed under the trademarks CoAprovel®, Avalide® and Karvezide® or any trademark that is confusingly similar to or that is a replacement for any such trademark. For the avoidance
of doubt, Irbesartan Products shall exclude any Fixed Dose Combination Products. 
 “Lease Agreement” means the
Business Lease Agreement between the SNC Partnership and Sanofi Winthrop Industrie, dated as of the date hereof. 
 “New
IP Agreement” means the FDC Intellectual Property License Agreement between Sanofi and BMS, dated as of the date hereof. 
 “Person” means any individual, partnership, firm, corporation, société anonyme, société en nom collectif, société en
participation, société par actions simplifiée, limited liability company, joint venture, association, trust or other entity or any government or any agency or political subdivision thereof, as well as any syndicate or
group that would be deemed to be a person under Section 13(d)(3) of the U.S. Securities Exchange Act of 1934, as amended. 

“Product” means a Clopidogrel Product or an Irbesartan Product and “Products” means both a Clopidogrel
Product and an Irbesartan Product. 
 “Territory A” means the countries and geographic areas described and
listed in Schedule 1A attached hereto. 
 “Third Party” means a Person who or which is neither a Party
nor an Affiliate of a Party. 
 “U.S.” or “United States” means any State or Commonwealth of
the United States of America, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa and any other territory, possession or military base of the United States of America. 

1.2 Additional Defined Terms. The following additional defined terms shall have the meanings set forth in the sections of this
Agreement listed below: 
  

			
	 Defined Term
	  	Section Where Defined
	 Agreement
	  	Preamble
	 Alliance Support Agreement
	  	Recitals
	 BMS
	  	Preamble
	 Clopidogrel
	  	Recitals
	 Clopidogrel License Agreement
	  	Recitals
	 Definitive Agreement
	  	Recitals

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 4 

			
	 Defined Term
	  	Section Where Defined
	 Development Agreement
	  	Recitals
	 Development Royalty

Dispute
 Dispute Resolution Notice
	  	4.1
 7.3

7.3

	 Force Majeure
	  	7.14
	 ICC
	  	7.3
	 IFRS
	  	1.1
	 Irbesartan
	  	Recitals
	 Irbesartan License Agreement
	  	Recitals
	 License Termination Date
	  	5.2
	 Notices
	  	7.1
	 Original Agreement
	  	Recitals
	 Party
	  	Preamble
	 Sanofi
	  	Preamble
	 SNC Partnership
	  	Preamble
	 Sterling
	  	Recitals

 ARTICLE 2 
 GRANT OF LICENSE 
 2.1 License Grant. Subject to the terms and
conditions of this Agreement, Sanofi and BMS each separately grant to the SNC Partnership an exclusive license for the term hereof in their respective undivided one-half direct ownership interest in the Developed Know-How, and the SNC Partnership
hereby accepts, an exclusive license for the term hereof under the Developed Know-How, to make, have made, sell, offer for sale and import the Products in Territory A; provided, however, that the foregoing exclusivity shall not apply to
Sanofi and BMS to the extent of their respective rights under the New IP Agreement with respect to Fixed Dose Combination Products and the manufacture of Irbesartan Products as set forth therein, and each of Sanofi and BMS retain all of their
respective rights under the Developed Know-How with respect to Fixed Dose Combination Products, subject to the licenses granted under the New IP Agreement. 
 2.2 No Transfer. The SNC Partnership hereby acknowledges and agrees that this Agreement does not, and shall not be deemed to, transfer any proprietary ownership interest whatsoever to the SNC
Partnership in or to the Developed Know-How. Nothing herein shall give the SNC Partnership any right, title or interest in or to any of the Developed Know-How, except the rights granted pursuant to this Agreement. 

2.3 No Implicit Rights. All of the rights granted hereunder are explicitly stated herein and nothing in this Agreement shall be
construed to grant any implied rights whatsoever to the SNC Partnership in or to the Developed Know-How. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 5 

 2.4 Goodwill. The SNC Partnership hereby acknowledges that all goodwill connected
with the Sanofi and BMS corporate names shall inure to the benefit of Sanofi and BMS, as the case may be, and the SNC Partnership shall not take any action that may be detrimental to such goodwill. 

2.5 Corporate Name Authorization. The SNC Partnership, Sanofi and its Affiliates shall be permitted to use the BMS Brands (as
defined in the Definitive Agreement) pursuant to and in accordance with Section 7.1 of the Definitive Agreement. 
 2.6
Location-Gérance. For the avoidance of doubt, Sections 2.2—2.4 hereof shall not prevent the SNC Partnership from leasing its business pursuant to the Lease Agreement. 

ARTICLE 3 

SUB-LICENSE 
 3.1 General Sub-License. The SNC Partnership shall not, without the prior written consent of both Sanofi and BMS, sub-license any of its rights and obligations under this Agreement, except as
permitted under, and subject to the terms of, the Lease Agreement. 
 3.2 Termination of Sub-License. Sanofi and BMS each
shall have the right to require the SNC Partnership to terminate any sub-license of rights hereunder in the event that the sub-licensee fails to comply in any material respect with, or takes any action contrary to, the terms of such sub-license, and
such sub-licensee has failed to remedy such non-compliance within thirty (30) days from its receipt of written notice thereof from Sanofi, BMS or the SNC Partnership. 
 ARTICLE 4 
 CONSIDERATION 

4.1 Development Royalty. In consideration of the rights and licenses granted hereunder, the SNC Partnership shall pay, or shall
cause to be paid, for the term of this Agreement the following aggregate amounts as a development royalty (each a “Development Royalty”), provided that, with respect to BMS, such royalty payments shall cease as of
December 31, 2018 and the license granted by BMS to the SNC Partnership under this Agreement shall become [*] and [*] as of such date: 
 (i) To each of Sanofi and BMS, an amount equal to [*] of IFRS Net Sales of Irbesartan Products in Territory A; and 
 (ii) To each of Sanofi and BMS, an amount equal to [*] of IFRS Net Sales of Clopidogrel Products in Territory A. 
 4.2 Payment. For the term of this Agreement, the SNC Partnership shall pay or cause to be paid to each of Sanofi and BMS all amounts due hereunder on a quarterly basis within sixty (60) days
of the end of each calendar quarter. Each such payment shall be accompanied by an accurate statement of the amount of IFRS Net Sales of the Products in Territory A, broken down Product-by-Product, during such calendar quarter and the calculation of
all payments to be made to each of Sanofi and BMS for such calendar quarter. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 6 

 4.3 Method of Payment. (a) All payments to be made hereunder shall be made by
wire transfer in immediately available funds, and shall be made in euros to the respective bank accounts of Sanofi and BMS as notified to the SNC Partnership by the relevant Party, unless the Parties agree to settle such payments through other
means. 
 (b) Amounts due from the SNC Partnership to BMS or Sanofi in respect of sales based on a currency other than Euros
shall be converted to Euros using the methodology determined for such purpose by Licensor in calculating IFRS Net Sales. 
 4.4
Records. The SNC Partnership shall maintain (i) books, records and accounts which accurately and fairly reflect, in reasonable detail, the IFRS Net Sales of the Products in Territory A and (ii) an adequate system of internal
accounting controls. All books, records and accounts referred to in clause (i) above shall be maintained for not less than [*] or for such longer period if and as required by applicable law, following the date of the sales constituting the IFRS
Net Sales and shall be made available for reasonable review upon request by Sanofi and/or BMS. 
 4.5 Taxes. All payments
due under this Agreement shall be paid in full without deduction, except for taxes (if any) required to be withheld by applicable law in Territory A with respect to such payments. In the event the SNC Partnership is required under applicable law to
withhold any tax to the revenue authorities in any country in Territory A regarding any payment to Sanofi and/or BMS, the amount of such tax shall be deducted by the SNC Partnership and paid to the relevant revenue authority, and the SNC Partnership
shall notify the relevant Party thereof and shall promptly furnish to such Party all copies of any tax certificate or other documentation evidencing such withholding. In the event that any such tax shall subsequently be found to be due, payment of
such tax shall be the responsibility of Sanofi or BMS, as the case may be. 
 ARTICLE 5 

TERM; TERMINATION 
 5.1 Term; Termination. (a) The term of this Agreement, with respect to each Product, shall commence on the date hereof and shall expire on December 31, 2018. Thereafter, this Agreement
shall be automatically renewed for successive three-year terms, respectively. 
 (b) The Parties may cause the early termination
of this Agreement by the mutual written consent of each of the Parties. 
 (c) Either BMS or Sanofi shall have the right to
declare termination of this Agreement upon Notice to the other Parties, following the first to occur of: 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 7 

 (i) such other Party shall have (A) voluntarily commenced any
proceeding or filed any petition seeking relief under Title 11 of the United States Code, Book VI of the French Commercial Code (legislative part as well as regulatory part) or any other bankruptcy, insolvency or similar law of the United States,
any state thereof, the French Republic or any other applicable jurisdiction, (B) applied for or consented to the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for all or
substantially all of its property, (C) filed an answer admitting the material allegations of a petition filed against or in respect of it in any such proceeding, (D) made a general assignment for the benefit of creditors of all or
substantially all of its assets, (E) become unable generally, or admitted in writing its inability to, pay all or substantially all of its debts as they become due or (F) taken corporate action for the purpose of effecting any of the
foregoing; or 
 (ii) an involuntary proceeding shall have been commenced or any involuntary petition shall have
been filed in a court of competent jurisdiction seeking (A) relief in respect of such other Party, or of its property, under Title 11 of the United States Code, Book VI of the French Commercial Code (legislative part as well as regulatory part)
or any other bankruptcy, insolvency or similar law of the United States, any state thereof, the French Republic or any other applicable jurisdiction, (B) the appointment of a receiver, trustee, custodian, sequestrator, conciliator,
administrator or similar official for such other Party or for all or substantially all of its property or (C) the winding-up or liquidation of such other Party; and such proceeding or petition shall have continued undismissed for sixty
(60) days or an order or decree approving or ordering any of the foregoing shall have continued unstayed and in effect for thirty (30) days. 
 5.2 Consequences of Termination. 
 (a) Upon the expiration or early
termination of this Agreement pursuant to Section 5.1 hereof (the “License Termination Date”): 
 (i) the
SNC Partnership shall cease, and shall cause each sub-licensee (if any) to cease, all activities related to the Developed Know-How; and 
 (ii) the SNC Partnership shall pay in full all amounts due to Sanofi and/or BMS hereunder within ten (10) days after the final determination of IFRS Net Sales for such period, including the License
Termination Date, pursuant to Sections 4.2, 4.3 and 4.5 hereof which shall survive until the full payment of all amounts under this clause (ii). 
 (b) Expiration or early termination of this Agreement pursuant to this Article 5 shall be without prejudice to any rights which shall have accrued to the benefit of any Party prior to such expiration
or termination. Such expiration or termination shall not relieve any Party from its obligations which are expressly indicated to survive the expiration or termination of this Agreement. All of the Parties’ rights and obligations under this
subclause (b) and under Sections 4.4, 4.5, 5.2 and 7.2—7.4 and Article 6 hereof shall survive such expiration or termination for the applicable period. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 8 

 ARTICLE 6 
 CONFIDENTIALITY 
 All of the data, material and information exchanged by
the Parties hereunder or related hereto (including, without limitation, the Developed Know-How) shall be subject to the confidentiality provisions of the Definitive Agreement as set forth in Section 8.8 thereof. 

ARTICLE 7 

MISCELLANEOUS 
 7.1 Notices. All notices, requests or other communications hereunder (collectively, “Notices”) shall be in writing, shall be in the English language and shall be given or made by
delivery in person, by courier service, by facsimile (with receipt confirmed) or by registered or certified mail (return receipt requested, with postage prepaid) to the respective Parties at the following addresses: 

If to Sanofi, to: 
 Sanofi 
 54, rue la Boétie 

75008 Paris, France 
 Attention: Senior Vice President, Legal Affairs and General Counsel 
 Facsimile:
(33.1) 53.77.43.03 
 Attention: Vice President, Alliances & Partnerships 

Facsimile: (33.1) 53.77.40.99 
 with a copy to: 
 Weil Gotshal & Manges 

767 Fifth Avenue 

New York NY 10153 

Attention: [omitted] 
 Facsimile: 212 310 8007 
 If to BMS, to: 

Bristol-Myers Squibb Company 
 P.O. Box 4000 
 Route 206 & Province Line Road 

Princeton, NJ 08543-4000 USA 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 9 

 Attention: Vice President and Associate General Counsel, Transactional Practice Group

 Facsimile: (1-609) 252-7680 
 with a copy to: 
 Wilmer Cutler Pickering Hale and Dorr LLP 

7 World Trade Center 
 250 Greenwich Street 
 New York, NY 10007 USA 

Attention: [omitted] 
 Facsimile: (212) 230-8888 
 If to the SNC Partnership, to: 

Sanofi Pharma Bristol-Myers Squibb 
 54, rue la Boétie 
 75008 Paris, France 

Attention: Senior Vice President, Legal Affairs and General Counsel 

Facsimile: (33.1) 53.77.43.03 
 Attention: Vice President, Alliances & Partnerships 

Facsimile: (33.1) 53.77.40.99 
 with a copy to: 
 Bristol-Myers Squibb Company 

P.O. Box 4000 

Route 206 & Province Line Road 
 Princeton, NJ 08543-4000 USA 
 Attention: Vice President and Associate General
Counsel, Transactional Practice Group 
 Facsimile: (1-609) 252-7680 
 or to such other address or facsimile number as hereafter shall be furnished as provided in this Section 7.1 by any Party hereto to the other Parties hereto. All Notices given to any Party in
accordance with this Section 7.1 shall be deemed to have been given on the date of receipt if delivered by hand or overnight courier service or sent by facsimile, or on the date ten (10) business days after dispatch by certified or
registered mail (postage prepaid) if mailed. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 10 

 7.2 Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of New York, United States of America, without regard to the choice of law principles that might otherwise be applied in such jurisdiction. 
 7.3 Dispute Resolution. 
 (a) Negotiation and Notice. In the event
of any dispute, claim, controversy or disagreement (each, a “Dispute”) arising out of, in connection with or relating to this Agreement including any question regarding this Agreement’s existence, validity or termination, the
Parties shall first seek resolution of such Dispute by negotiation between their respective senior management. Such negotiation shall be deemed to commence upon the service by either Sanofi or BMS upon the other of a written notice (a
“Dispute Resolution Notice”) under this Section 7.3(a). 
 (b) If a Dispute subject to negotiation
under Section 7.3(a) is not finally resolved within thirty (30) days following receipt by either Sanofi or BMS of a Dispute Resolution Notice, the Dispute shall be finally resolved by arbitration under the Rules of Arbitration of
the International Chamber of Commerce (the “ICC”). The arbitral tribunal shall be composed of three (3) arbitrators. Each of Sanofi and BMS shall nominate one (1) arbitrator. The two (2) arbitrators so nominated shall
nominate the presiding arbitrator. If either Sanofi or BMS fails to nominate an arbitrator in its Request for Arbitration or within thirty (30) days of receiving written notice of the nomination of an arbitrator by the other Party, such
arbitrator shall be appointed by the ICC Court. If the two (2) arbitrators to be nominated by Sanofi and BMS fail to agree upon a third arbitrator within thirty (30) days of the nomination of the second arbitrator, the third arbitrator
shall be appointed by the ICC Court. The place of arbitration shall be Paris, France and the language of the arbitration shall be English. Notwithstanding any provision to the contrary in the ICC Rules of Arbitration, each Party shall bear its own
costs and expenses relating to such arbitration and all related proceedings, including fees for legal representation. Each Party shall continue to perform its respective obligations under this Agreement and this Agreement shall remain in effect
while the Dispute is being resolved. The Parties agree that any dispute arising out of or relating to this Agreement, the Definitive Agreement, or the Settlement Agreement (including the China Opt-Out Letter) or any Alliance Agreement (as such terms
are defined in the Definitive Agreement) shall be resolved in a single arbitration before the ICC, regardless of how many parties or agreements are implicated, and specifically waive any argument that a dispute arising out of or relating to this
Agreement shall be resolved in multiple arbitrations before the ICC. 
 7.4 Specific Performance. Each Party agrees that
the Developed Know-How is unique, and each Party hereby acknowledges and agrees that it and the other Parties would be damaged irreparably if any of the provisions of this Agreement are not performed in accordance with their specific terms or
otherwise are breached. Accordingly, each Party shall be entitled to seek specific performance and/or interim relief, and agrees that the arbitral tribunal constituted under Section 7.3(b) shall have the power to order specific performance or
grant provisional, interim, or conservatory measures, including but not limited to provisional injunctive relief. The Parties undertake to comply forthwith with any such provisional, interim, or conservatory

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 11 

 
measures ordered by the arbitral tribunal and agree that such measures may, to the extent not precluded by applicable law, be enforceable as a final award in any court of competent jurisdiction.
For the avoidance of doubt, nothing in this provision shall prevent any Party from seeking conservatory or interim measures, including, but not limited to, temporary restraining orders or preliminary injunctions or their equivalent, from any court
of competent jurisdiction before the arbitral tribunal is constituted under Section 7.3(b) or, thereafter, upon the order of the arbitral tribunal. 
 7.5 No Third Party Beneficiaries. This Agreement shall be binding upon and inure solely to the benefit of the Parties (including the partners of the SNC Partnership, each in its capacity as partner
thereof) and permitted sub-licensees and assigns, and nothing herein, express or implied, is intended to, or shall confer upon, any other Person any legal or equitable right, benefit or remedy of any nature whatsoever. 

7.6 Assignment. 
 (a) No Party hereto may assign any of its rights or obligations to a Third Party under this Agreement without the prior written consent of the other Parties and any assignment without such consent shall
be null and void and of no effect. Each Party may assign any of its rights or obligations under this Agreement to an Affiliate of such Party without the written consent of the other Parties, provided that the assigning Party shall remain liable for
its Affiliate’s performance hereunder. 
 (b) In no event shall the SNC Partnership or its Affiliates be restricted in
their ability to appoint distributors for Products or to sublicense their rights hereunder in accordance with the terms hereof, so long as such appointment or sublicensing does not or would not reasonably be expected to result in an assignment in
violation of this Section 7.6. Notwithstanding the foregoing, Sanofi and its Affiliates shall be permitted to assign this Agreement without BMS’s consent in connection with any divestiture permitted under Section 12.7 of the
Definitive Agreement. 
 7.7 Severability. If any term or other provision hereof is held to be invalid, illegal or
incapable of being enforced by applicable law or public policy, all other terms and provisions hereof shall nevertheless remain in full force and effect so long as the economic effect or legal substance of the transactions contemplated hereby is not
affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect
the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. 

7.8 Waivers and Amendments. No modification of or amendment to this Agreement shall be valid unless (i) in a writing signed
by the Parties referring specifically to this Agreement and stating the Parties’ intention to modify or amend the same and (ii) BMS has provided its prior written consent to such modification or amendment. Any waiver of any term or
condition 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 12 

 
of this Agreement shall be in a writing signed by the Party sought to be charged with such waiver referring specifically to the term or condition to be waived, and no such waiver shall be deemed
to constitute the waiver of any other breach of the same or of any other provision hereof. 
 7.9 Headings. All titles
and captions contained in this Agreement are for the convenience of reference only and shall not affect in any way the meaning or interpretation hereof. 
 7.10 Entire Agreement. This Agreement constitutes the entire agreement of the Parties with respect to the subject matter contained herein and all prior agreements relative thereto which are not
contained herein are hereby terminated. 
 7.11 No Partnership or Joint Venture. This Agreement is not intended to
create, and nothing contained herein shall be construed to create an association, joint venture, trust or partnership, or to impose a trust or partnership covenant, obligation or liability on or with regard to the other Party. Each Party shall be
severally responsible for its own covenants, obligations and liabilities as herein provided. Other than the SNC Partnership: (i) no Party shall be under the control of, or shall be deemed to control any other Party; (ii) no Party is the
legal representative, agent, joint venturer or employee of the other Party with respect to this Agreement for any purpose whatsoever, and no Party shall have the right or power to bind the other Party; and (iii) no Party has the right or
authority to assume or create any obligations of any kind or to make any representation or warranty on behalf of any other Party, whether express or implied, or to bind any other Party in any respect whatsoever. The provisions of this Agreement are
intended only for the regulation of relations between the Parties. This Agreement is not intended for the benefit of non-Party creditors, and no rights are granted to non-Party creditors under this Agreement. 

7.12 Governing Language. The Parties acknowledge that this Agreement may be translated into the French language. The Parties agree
that this English language version shall in all respects be the controlling version of this Agreement. 
 7.13
Counterparts. This Agreement may be executed in one or more counterparts, each of which when executed shall be deemed to be an original, but all of which when taken together shall constitute one and the same agreement. 

7.14 Force Majeure. No Party shall be in default under this Agreement, or shall have any obligation to the other Party, if such
Party is unable to perform under this Agreement by reason of act of God, fire, flood, strike, national emergency or other contingency beyond its reasonable control (a “Force Majeure”). Such Party shall give the other Party prompt
notice of any interruption of performance on account of Force Majeure, and of the resumption of such performance, and shall keep the other Party informed on a current basis as to the steps being taken to remove, and the anticipated time of removal
of, the circumstances resulting in such Force Majeure. Notwithstanding the foregoing, nothing in this Section 7.14 shall excuse or suspend the obligation to make any payment due under this Agreement in the manner and at the time provided
herein. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 13 

 7.15 Definitive Agreement. For so long as (i) the SNC Partnership is a party to
this Agreement and (ii) BMS retains any direct or indirect ownership interest in the SNC Partnership, in the event of any conflict or inconsistency between any provision of this Agreement and the terms of the Definitive Agreement, the
Definitive Agreement shall govern with respect to such provision. 
 [Remainder of Page Intentionally Left Blank]

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 14 

 IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the day and year
first written above. 
  

									
	SANOFI	 		 	SANOFI PHARMA BRISTOL-MYERS SQUIBB
				
		 		 		 	Represented by:
				
	By:	 	/s/ Thierry Saugier	 		 	SANOFI PARTICIPATIONS
		 	 Name: Thierry Saugier

Title:   Authorized representative
	 		 	By:	 	/s/ Thierry Saugier
		 		 		 		 	Name: Thierry Saugier
	BRISTOL-MYERS SQUIBB COMPANY	 		 		 	Title:   Authorized representative
		 		 		 		 	
		 		 		 	Witnessed by:
	By:	 	/s/ Katherine Kelly	 		 		 	
		 	Name: Katherine Kelly	 		 	BMS INVESTCO S.A.S.
		 	Title:   Assistant Secretary	 		 		 	
		 		 		 	By:	 	/s/ Jean-Christophe Barland
		 		 		 		 	Name: Jean-Christophe Barland
		 		 		 		 	Title:   CEO

 [Signature Page to Amended and Restated Territory A Know-How License] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 SCHEDULE 1A 

TERRITORY
A1 

For Clopidogrel Products: 
  

	-	Austria 

	-	France (metropolitan) 

	-	Belgium 

	-	Cyprus 

	-	Denmark 

	-	Finland 

	-	Germany 

	-	Greece 

	-	Hong-Kong 

	-	Iceland 

	-	Ireland 

	-	Israel 

	-	Italy 

	-	Korea 

	-	Norway 

	-	United Kingdom 

	-	the Netherlands 

	-	Portugal 

	-	Spain 

	-	Sweden 

	-	Switzerland 

	-	Taiwan 

 For Irbesartan Products: 

 

	-	France (including overseas territories) 

	-	Belgium 

	-	Germany 

	-	Greece 

	-	Italy 

	-	United Kingdom 

	-	the Netherlands 

	-	Portugal 

	-	Spain 

	-	Switzerland 

  

	1 	Territory A will be deemed to include any new country created by the division, consolidation or name change of the countries listed below. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSIONEX-10.y

 Exhibit 10y 
 *Confidential Treatment Requested 
  

 
 AMENDED AND RESTATED 

TERRITORY B PRODUCT KNOW-HOW LICENSE AGREEMENT 
 among 
 SANOFI 

BRISTOL-MYERS SQUIBB COMPANY 
 and 
 BRISTOL-MYERS SQUIBB SANOFI PHARMACEUTICALS HOLDING PARTNERSHIP 

dated as of January 1, 2013 
  

 
 *CONFIDENTIAL TREATMENT
REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 TABLE OF CONTENTS 

 

							
	ARTICLE 1	  
	DEFINITIONS	  
			
	 1.1
	 	 Defined Terms
	  	 	2	  
	 1.2
	 	 Additional Defined Terms
	  	 	4	  
	
	ARTICLE 2	  
	GRANT OF LICENSE	  
			
	 2.1
	 	 License Grant
	  	 	5	  
	 2.2
	 	 No Transfer
	  	 	5	  
	 2.3
	 	 No Implicit Rights
	  	 	6	  
	 2.4
	 	 Corporate Name Authorization
	  	 	6	  
	 2.5
	 	 Goodwill
	  	 	6	  
	 2.6
	 	 Improvements
	  	 	6	  
	 2.7
	 	 Original License
	  	 	6	  
	
	ARTICLE 3	  
	SUB-LICENSE	  
			
	 3.1
	 	 General Sub-License
	  	 	6	  
	 3.2
	 	 Sub-License for Alliance Agreements
	  	 	6	  
	 3.3
	 	 Termination of Sub-License
	  	 	7	  
	
	ARTICLE 4	  
	CONSIDERATION	  
			
	 4.1
	 	 Development Royalty
	  	 	7	  
	 4.2
	 	 Payment
	  	 	7	  
	 4.3
	 	 Method of Payment
	  	 	7	  
	 4.4
	 	 Records
	  	 	7	  
	 4.5
	 	 Payment Reports
	  	 	7	  
	 4.6
	 	 Taxes
	  	 	8	  
	
	ARTICLE 5	  
	LICENSE STEERING COMMITTEE	  
			
	 5.1
	 	 License Steering Committee
	  	 	8	  
	 5.2
	 	 License Functional Committees
	  	 	8	  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 i 

							
	 5.3
	 	 Committee Composition and Decision Making
	  	 	9	  
	 5.4
	 	 Committee Dispute Resolution
	  	 	9	  
	 5.5
	 	 Delegation
	  	 	9	  
	
	ARTICLE 6	  
	NEW INDICATION OR LINE EXTENSION	  
	SOLE RISK SCENARIO	  
			
	 6.1
	 	 Sole Development
	  	 	9	  
	 6.2
	 	 Commercialization of Resulting Products
	  	 	10	  
	 6.3
	 	 [*]
	  	 	10	  
	 6.4
	 	 Election to Participate in Development
	  	 	10	  
	 6.5
	 	 Period of Exclusivity
	  	 	10	  
	 6.6
	 	 Safety and Other Problems
	  	 	11	  
	
	ARTICLE 7	  
	TERM; TERMINATION	  
			
	 7.1
	 	 Term; Termination
	  	 	11	  
	 7.2
	 	 Consequences of Termination
	  	 	12	  
	
	ARTICLE 8	  
	CONFIDENTIALITY	  
	
	ARTICLE 9	  
	MISCELLANEOUS	  
			
	 9.1
	 	 Notices
	  	 	13	  
	 9.2
	 	 Governing Law
	  	 	15	  
	 9.3
	 	 Dispute Resolution
	  	 	15	  
	 9.4
	 	 Specific Performance
	  	 	16	  
	 9.5
	 	 No Third Party Beneficiaries
	  	 	16	  
	 9.6
	 	 Assignment
	  	 	16	  
	 9.7
	 	 Severability
	  	 	17	  
	 9.8
	 	 Waivers and Amendments
	  	 	17	  
	 9.9
	 	 Headings
	  	 	17	  
	 9.10
	 	 Entire Agreement
	  	 	17	  
	 9.11
	 	 No Partnership or Joint Venture
	  	 	17	  
	 9.12
	 	 Governing Language
	  	 	18	  
	 9.13
	 	 Counterparts
	  	 	18	  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 ii 

 This AMENDED AND RESTATED TERRITORY B PRODUCT KNOW-HOW LICENSE AGREEMENT (this
“Agreement”) dated as of January 1, 2013 is hereby made by and among: 
 Sanofi, a
société anonyme organized and existing under the laws of the French Republic (“Sanofi”); 

Bristol-Myers Squibb Company, a corporation organized and existing under the laws of the State of Delaware, United States of America
(“BMS”); and 
 Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, a Delaware partnership (the
“Partnership” and, together with Sanofi and BMS, the “Parties” and, individually, each a “Party”). 
 W I T N E S S E T H: 
 WHEREAS, Sanofi previously discovered and
patented a new chemical entity, known as SR 25990C with the international non-proprietary name Clopidogrel Hydrogenosulphate (“Clopidogrel”); 
 WHEREAS, Sanofi, BMS and Sterling Winthrop Inc., a Delaware corporation (“Sterling”) entered into a Development Agreement dated July 29, 1993 (the “Development
Agreement”) for, among other things, the development of Clopidogrel; 
 WHEREAS, pursuant to an Amended and Restated
Asset Purchase Agreement dated as of September 30, 1994 among Eastman Kodak Company, Sanofi and Sterling, Sanofi acquired certain assets, and assumed certain obligations, of the ethical pharmaceutical business of Sterling, including the rights
and obligations of Sterling under the Development Agreement; 
 WHEREAS, Sanofi and BMS have entered into a Territory B Alliance
Support Agreement dated as of January 1, 1997, as amended as of the date hereof (the “Alliance Support Agreement”) and have formed through their indirect wholly owned subsidiaries the Partnership pursuant to the partnership
agreement dated as of January 1, 1997, as amended as of the date hereof (the “Partnership Agreement”) for, among other things, the commercialization of the Products in certain territories, including Territory B (as such terms
are defined herein); 
 WHEREAS, Sanofi and the Partnership have entered into a Clopidogrel Intellectual Property License and
Supply Agreement, dated as of January 1, 1997 and amended and restated as of the date hereof, pursuant to which Sanofi granted a license to the Partnership to use certain patents, trademarks and know-how for the commercialization of the
Products in certain territories, including Territory B, that neither were developed with nor are owned by BMS; 
 WHEREAS,
Sanofi and BMS have developed certain know-how under the Development Agreement for the commercialization of the Products in certain territories, including Territory B and, as a result, each has an undivided one-half direct ownership interest in the
Developed Know-How (as such term is defined herein); 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 WHEREAS, Sanofi, BMS and the Partnership have entered into a Product Know-How License
Agreement dated as of January 1, 1997 (the “Original License”), pursuant to which Sanofi and BMS have granted to the Partnership a license under the Developed Know-How for the commercialization of the Products in certain
territories, including Territory B; 
 WHEREAS, the Partnership has been commercializing Products in Territory B since that
date; 
 WHEREAS, pursuant to the Master Restructuring Agreement (the “Definitive Agreement”), dated as of
September 27, 2012, by and between Sanofi and BMS, Sanofi and BMS have agreed to simplify the overall governance, operating and financial principles of their alliance with respect to the Products, other than Clopidogrel in the United States
(including Puerto Rico); and 
 WHEREAS, in connection with the transactions contemplated by the Definitive Agreement, Sanofi
and BMS have agreed to, among other things, amend and restate the Original License on the terms set forth herein. 
 NOW,
THEREFORE, in consideration of the mutual covenants and the terms and conditions set forth herein, the Parties hereby agree as follows: 
 ARTICLE 1 
 DEFINITIONS 

1.1 Defined Terms. As used in this Agreement, the following terms shall have the following meanings: 

“Affiliate”, when used with reference to any Person, means any other Person controlling, controlled by, or under common
control with, such Person; provided, however, that, with respect to Sanofi, the definition of Affiliate shall exclude L’Oréal, a société anonyme organized and existing under the laws of the French Republic.
For the purposes of this definition, “control” shall refer to (a) the possession, directly or indirectly, of the power to direct the management or policies of a Person or to veto any material decision relating to the management
or policies of a Person, in each case whether through the ownership of voting securities, by contract or otherwise, (b) the beneficial ownership, directly or indirectly, of securities (excluding general partnership interests) representing at
least 50% of the voting power of all outstanding voting securities of a Person or (c) the beneficial ownership of at least 50% of the partnership interests of a general partnership. The Parties confirm that each Co-Promotion Entity (as defined
in the Alliance Support Agreement) in Territory B shall be considered to be an Affiliate of BMS. 
 “Alliance
Agreements” has the meaning set forth in the Alliance Support Agreement. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -2-

 “Alliance Strategic Committee” has the meaning set forth in the Alliance
Support Agreement. 
 “Clopidogrel Bulk” means the active substance chemical bulk containing Clopidogrel.

 “Clopidogrel Product” means the product or products having as an active ingredient Clopidogrel or any salt,
ester, metabolite or pro-drug thereof. 
 “Developed Know-How” means any and all technical data, information,
material and other know-how that relate to the formulation of the Products, including, without limitation, any analytical methodology, chemical, toxicological, pharmacological and clinical data, formulae, procedures, protocols, techniques and
results of experimentation and testing, developed by Sanofi and BMS under the Development Agreement. 
 “Finance
Committee” has the meaning set forth in the Alliance Support Agreement. 
 “fixed dose combination”
means a pharmaceutical dosage form containing fixed doses of more than one active ingredient in which all active ingredients are present in a single tablet, capsule or other form and shall expressly exclude so-called “co-packaging” in
which separate drugs in separate dosage forms are sold in a single unit or bundle. 
 “Fixed Dose Combination
Product” means a fixed dose combination containing Clopidogrel. 
 “Functional Committee” means any
Alliance Functional Committee (as such term is defined in the Alliance Support Agreement) or any License Functional Committee. 

“Governmental Authority” means any federal, state or local or any foreign or supranational government, governmental,
regulatory or administrative authority, agency or commission or any court, tribunal or judicial or arbitral body. 

“Lead” means the right to initiate proposals and implement, or cause the implementation of, recommendations and
decisions. 
 “Line Extension” means, with respect to development conducted on or after the date hereof, any
new dosage or new form of administration of any Product. 
 “Marketing Entity” has the meaning set forth in the
Partnership Agreement. 
 “Net Sales” means for any given period and with respect to any Product, the gross
amount invoiced in respect thereof by the Marketing Entities to any Person (excluding any transfers between any Party and its Affiliates solely for purposes of resale, promotional use or clinical trials), less (i) quantity and/or cash
discounts, allowances and/or rebates actually allowed or given, (ii) freight, postage and shipping insurance expenses (if separately identified in such 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -3-

 
invoice), (iii) sales taxes directly related to the sale to the extent included in the gross invoice price (but not including taxes assessed against the income derived from such sale) and
(iv) amounts repaid or credited on account of rejections, outdating or the return of such Product. 
 “New
Indication” means, with respect to development conducted on or after the date hereof, any new therapeutic use or application of any Product. 
 “New IP Agreement” means the FDC Intellectual Property License Agreement between Sanofi and BMS, dated as of the date hereof. 

“Person” means any individual, partnership, firm, corporation, société anonyme, société
en nom collectif, société en participation, société par actions simplifiée, limited liability company, joint venture, association, trust or other entity or any government or any agency or political subdivision
thereof, as well as any syndicate or group that would be deemed to be a person under Section 13(d)(3) of the U.S. Securities Exchange Act of 1934, as amended. 
 “Product” means a Clopidogrel Product. 
 “Safety
Problem” has the meaning set forth in the Alliance Support Agreement. 
 “Territory B” or the
“United States” means any State or Commonwealth of the United States of America, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa and any other territory, possession or military base of the United
States of America. 
 “Third Party” means a Person who or which is neither a Party nor an Affiliate of a Party.

 1.2 Additional Defined Terms. The following additional defined terms shall have the meanings set forth in the sections
of this Agreement listed below: 
  

			
	 Defined Term
	  	Section Where Defined
	Agreement	  	Preamble
	Alliance Support Agreement	  	Recitals
	BMS	  	Preamble
	Clopidogrel	  	Recitals
	Definitive Agreement	  	Recitals
	Development Agreement	  	Recitals
	Development Committee	  	5.2
	Development Royalty	  	4.1
	Dispute	  	9.3(a)
	Dispute Resolution Notice	  	9.3(a)
	ICC	  	9.3(b)
	License Functional Committees	  	5.2

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -4-

			
	 Defined Term
	  	Section Where Defined
	License Steering Committee	  	5.1
	License Strategic Decisions	  	5.1
	License Termination Date	  	7.2
	Notices	  	9.1
	Original License	  	Recitals
	Other Party	  	6.1
	Partnership Agreement	  	Recitals
	Partnership	  	Preamble
	Party	  	Preamble
	Payment Report	  	4.2
	Proposing Party	  	6.1
	Sanofi	  	Preamble
	Sterling	  	Recitals

 ARTICLE 2 
 GRANT OF LICENSE 
 2.1 License Grant. Subject to the terms and
conditions of this Agreement, Sanofi and BMS each separately grant to the Partnership an exclusive license for the term hereof in their respective undivided one-half direct ownership interest in the Developed Know-How, and the Partnership hereby
accepts, an exclusive license for the term hereof under the Developed Know-How (i) to sell, offer for sale and import, and, with respect to BMS as licensor only, to make and have made, the Products in Territory B, and (ii) subject to
Article 6 hereof, to develop Products for Territory B, including, without limitation, New Indications and Line Extensions thereof; provided, however, that the foregoing exclusivity shall not apply to Sanofi and BMS to the extent of their
respective rights (both granted and retained) under the New IP Agreement with respect to Fixed Dose Combination Products. 

Subject to the occurrence of a change in exclusivity of supply under Section 4.3 of the Plavix Finished Product Supply Agreement
between sanofi-aventis U.S. LLC, as supplier, and the Partnership, as purchaser, dated as of the date hereof, Sanofi hereby grants to the Partnership, subject to the terms and conditions of this Agreement, an exclusive license under its undivided
one-half direct ownership interest in the Developed Know-How to manufacture and package, or have manufactured and packaged, the Products for sale in Territory B, for the term and to the extent needed to cover the period of exclusivity change.

 2.2 No Transfer. The Partnership hereby acknowledges and agrees that this Agreement does not, and shall not be deemed
to, transfer any proprietary ownership interest whatsoever to the Partnership in or to the Developed Know-How. Nothing herein shall give the Partnership any right, title or interest in or to any of the Developed Know-How, except the rights granted
pursuant to this Agreement. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -5-

 2.3 No Implicit Rights. All of the rights granted hereunder are explicitly stated
herein and nothing in this Agreement shall be construed to grant any implied rights whatsoever to the Partnership in or to the Developed Know-How. 
 2.4 Corporate Name Authorization. The Partnership shall be permitted to use both the Sanofi and BMS corporate names, on a [*] basis for the term hereof, solely (i) as part of its corporate
name and (ii) in connection with any promotional, advertising or marketing necessary or desirable for the commercialization of the Products in Territory B in accordance with this Agreement and the Alliance Support Agreement. The grant of rights
pursuant to this Section 2.4 shall terminate upon the earlier of (i) the expiration or early termination of this Agreement and (ii) the expiration or early termination of the Alliance Support Agreement, provided that such
termination shall not affect any continuing rights to BMS’s corporate name(s) that Sanofi and its Affiliates may have pursuant to Section 7.1 of the Definitive Agreement. 

2.5 Goodwill. The Partnership hereby acknowledges that all goodwill connected with the Sanofi and BMS corporate names shall inure
to the benefit of Sanofi and BMS, as the case may be, and the Partnership shall not take any action that may be detrimental to such goodwill. 
 2.6 Improvements. Any new or useful invention, process or improvement, patentable or unpatentable, relating to the formulation of any Product under the Developed Know-How developed or acquired by
the Partnership during the term hereof, shall be the property of the Partnership which shall have all ownership rights thereto, subject to Article 6 hereof. 
 2.7 Original License. The Parties hereby agree that all acts, omissions and occurrences prior to the date hereof, and all rights and obligations of the Parties with respect thereto, shall be
governed by the terms of the Original License prior to its amendment and restatement in accordance with the terms hereof. 

ARTICLE 3 

SUB-LICENSE 
 3.1 General Sub-License. Except as permitted under Section 3.2 hereof, the Partnership shall not, without the prior written consent of both Sanofi and BMS, sub-license any of its rights and
obligations under this Agreement; provided, however, that if the representatives of Sanofi and BMS on any Functional Committee, the Alliance Strategic Committee or the License Steering Committee, consensually agree to sub-license any of the
Partnership’s rights or obligations hereunder, such agreement shall be deemed to be the consent of Sanofi and BMS for the purposes of this Section 3.1. No such sub-license shall relieve the Partnership of its obligations hereunder.

 3.2 Sub-License for Alliance Agreements. The Partnership shall sub-license those of its rights and obligations under
this Agreement, to any Affiliate of Sanofi or BMS that is a party to any Alliance Agreement, solely for the purposes of permitting such Affiliate to perform its obligations under such Alliance Agreement. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -6-

 3.3 Termination of Sub-License. Sanofi and BMS each shall have the right to require
the Partnership to terminate any sub-license of rights hereunder in the event that the sub-licensee fails to comply in any material respect with, or takes any action contrary to, the terms of such sub-license or any decision made by any Functional
Committee, the Alliance Strategic Committee or the License Steering Committee, and such sub-licensee has failed to remedy such non-compliance within thirty (30) days from its receipt of written notice thereof from Sanofi, BMS or the
Partnership. 
 ARTICLE 4 
 CONSIDERATION 
 4.1 Development Royalty. In consideration of the
rights and licenses granted hereunder, the Partnership shall pay, or shall cause to be paid, for the term of this Agreement, as a development royalty (the “Development Royalty”) to [*], an amount equal to [*] of Net Sales of
Clopidogrel Products in Territory B. 
 4.2 Payment. For the term of this Agreement, the Partnership shall pay or cause
to be paid to each of Sanofi and BMS all amounts due hereunder on a quarterly basis within sixty (60) days of the end of each calendar quarter. Each such payment shall be accompanied by an accurate statement of the amount of Net Sales of the
Products in Territory B during such calendar quarter and the calculation of all payments to be made to each of Sanofi and BMS for such calendar quarter (each a “Payment Report”). 

4.3 Method of Payment. (a) All payments to be made hereunder shall be made by wire transfer in immediately available funds,
and shall be made in US dollars to the respective bank accounts of Sanofi and BMS as notified to the Partnership by the relevant Party, unless the Parties agree to settle such payments through other means. 

4.4 Records. The Partnership shall maintain (i) books, records and accounts which accurately and fairly reflect, in
reasonable detail, the Net Sales of the Products in Territory B and (ii) an adequate system of internal accounting controls. All books, records and accounts referred to in clause (i) above shall be maintained for not less than [*], or for
such longer period if and as required by applicable law, following the date of the sales constituting the Net Sales and shall be made available for reasonable review upon request by Sanofi and/or BMS. 

4.5 Payment Reports. (a) At the request of Sanofi, the Partnership shall, and shall if applicable cause its sub-licensees to,
permit Sanofi or an independent, certified public accountant not having any significant relation to either BMS or Sanofi, as appointed by Sanofi, at reasonable times and upon reasonable notice, to examine the books and records of the Partnership as
may be necessary to (i) determine, with respect to any calendar quarter ending not more than [*] prior to the related request, the correctness of any Payment Report or payment made under this Agreement or any Alliance Agreement or
(ii) obtain information as to the 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -7-

 
amount payable for any such calendar quarter in the case of failure on the part of the Partnership to report or pay pursuant to this Agreement or on the part of any party to any Alliance
Agreement; provided, however, that Sanofi shall not have the right to make such audit request more than once every [*]. The results of any such audit shall be promptly made available to BMS, Sanofi and the Partnership. 

(b) Sanofi shall bear the full cost and expense of any such audit, unless such audit discloses that the amount due to Sanofi is more than
the amount paid by [*] of the amount due, in which case BMS shall bear the full cost and expense of such audit. 
 (c) The
determination by an independent, certified public accountant pursuant to this Section 4.5 as to the amount due and payable by the Partnership shall be conclusive and binding on the Parties hereto. 

4.6 Taxes. All payments due under this Agreement shall be paid in full without deduction, except for taxes (if any) required to be
withheld by applicable law in Territory B with respect to such payments. In the event the Partnership is required under applicable law to withhold any tax to the revenue authorities in any country in Territory B regarding any payment to Sanofi
and/or BMS, the amount of such tax shall be deducted by the Partnership and paid to the relevant revenue authority, and the Partnership shall notify the relevant Party thereof and shall promptly furnish to such Party all copies of any tax
certificate or other documentation evidencing such withholding. In the event that any such tax shall subsequently be found to be due, payment of such tax shall be the responsibility of Sanofi or BMS, as the case may be. 

ARTICLE 5 

LICENSE STEERING COMMITTEE 
 5.1 License Steering Committee. In order to ensure the proper use of the Developed Know-How by the Partnership for the commercialization and further development of the Products, Sanofi and BMS
shall be represented by a License Steering Committee (the “License Steering Committee”), which shall be responsible for the following (collectively, the “License Strategic Decisions”): 

(i) overseeing the commercialization of the Products in Territory B and taking decisions on any operational
disagreements; 
 (ii) approving the annual operating budget for Territory B and any requests for New Indications
and Line Extensions; and 
 (iii) overall pricing guidelines and any exceptions to the same. 

5.2 License Functional Committees. The License Steering Committee may establish, at its discretion, functional committees (the
“License Functional Committees”) as needed to manage the conduct of the ongoing business in Territory B and exchange of necessary information between BMS and Sanofi, including a development committee (“Development
Committee”). 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -8-

 5.3 Committee Composition and Decision Making. The License Steering Committee shall
at all times consist of six (6) representatives, three (3) of whom shall represent Sanofi and three (3) of whom shall represent BMS. The representatives of Sanofi shall be the persons serving from time to time as the (i) VP
– General Therapeutics – North America, (ii) Vice President and Chief Financial Officer – North America, and (iii) Vice President, Alliance Management, Sanofi. The representatives of BMS shall be the persons serving from to
time as the (i) Senior Vice President – CV/Met, (ii) Vice President – U.S. Finance, and (iii) Head of Global Alliances. If any such position has been modified or eliminated, the Party so affected shall appoint an individual
whose position is substantially similar to the position so modified or eliminated. The License Steering Committee shall have the sole power, by a consensus of the representatives of Sanofi and BMS, to make any and all License Strategic Decisions and
to resolve any deadlock or conflict arising among or within the License Functional Committees that has not been resolved pursuant to the Alliance Support Agreement. 
 5.4 Committee Dispute Resolution. All disputes arising within the License Steering Committee shall be resolved pursuant to Section 3.06 of the Alliance Support Agreement; provided, however,
that if agreement cannot be reached with respect to the [*] for any fiscal year pursuant to Section 3.06 of the Alliance Support Agreement, the [*] for the previous fiscal year shall carry over to the next fiscal year, until the [*] for the
next fiscal year shall have been approved. 
 5.5 Delegation. The License Steering Committee may, by a consensus of the
representatives of Sanofi and BMS thereon, expressly and by written resolution establish any other functional committee and delegate its powers to such newly established functional committee and/or to any then existing License Functional Committee
on such terms as it deems appropriate. 
 ARTICLE 6 

NEW INDICATION OR LINE EXTENSION 
 SOLE RISK SCENARIO 
 6.1 Sole Development. If either Sanofi or BMS
wishes to pursue the development of any New Indication or Line Extension, such Party (the “Proposing Party”) shall propose such development to the other Party (the “Other Party”) in the context of the Development
Committee. If the Other Party decides not to pursue such development, as evidenced by its negative vote in the Development Committee with respect to such development and irrespective of whether such Party has the Lead for the Product with respect to
which such development is proposed, then the Development Committee shall submit such proposal to the License Steering Committee, which shall decide whether the Proposing Party may proceed alone with such development. If the License Steering
Committee agrees to permit such sole development, the Proposing Party shall be entitled to undertake such development at its sole cost and expense. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -9-

 6.2 Commercialization of Resulting Products. If the Proposing Party proceeds alone
with such development pursuant to Section 6.1 hereof, the Proposing Party and the Other Party shall, and shall cause their respective Affiliates to, grant the rights for the development of such New Indication or Line Extension, as the case may
be, to the Proposing Party (with the right to sub-license to its Affiliates with the consent of the Other Party (which such consent shall not be unreasonably withheld)) solely for the purposes of pursuing such development in accordance with the
terms of this Agreement. In the event the Proposing Party successfully develops such New Indication or Line Extension, the Proposing Party hereby acknowledges and agrees that (i) pursuant to Section 2.1 hereof, solely the Partnership shall
have the right to commercialize such New Indication or Line Extension in Territory B, subject to BMS and Sanofi’s respective rights under the New IP Agreement with respect to Fixed Dose Combination Products and (ii) such commercialization
shall be fully subject to and performed in accordance with the decisions and recommendations of the Alliance Strategic Committee, the License Steering Committee and the Functional Committees in accordance with this Agreement and the Alliance Support
Agreement. 
 6.3 [*] In the event of such sole development, the Proposing Party shall be entitled to receive an [*] for
such development equal to [*] which shall be [*] payable to such Party pursuant to Article 4 hereof. In the event that the Finance Committee cannot agree upon a method of [*], including the [*] payable under Section [*] hereof, the Proposing Party
and the Other Party shall [*]. The [*], and the fees and expenses of [*] shall be [*]. 
 6.4 Election to Participate in
Development. The Other Party may reverse its election not to pursue such development, by Notice to the Proposing Party, at any time prior to the registration of such New Indication or Line Extension in the first country in Territory B in which
registration is made, subject to the reimbursement of [*] of all [*] incurred by the Proposing Party with respect to such New Indication or Line Extension as of the date on which such Notice is made. In the event of such reimbursement, the Proposing
Party and the Other Party shall thereafter share [*] incurred after the date on which such Notice is made with respect to such development, and [*] set forth in Section [*] hereof shall be [*] by [*], from [*] to [*] of Net Sales of the Product in
Territory B [*]; provided, however, that only the Proposing Party shall be entitled to [*]. 
 6.5 Period of
Exclusivity. If the development undertaken by the Proposing Party results in (i) an additional period of legal and de facto exclusivity for the Product as a whole or (ii) the issuance of a new patent for such New Indication or
Line Extension developed through such development resulting in legal and de facto exclusivity for such New Indication or Line Extension, then the Proposing Party also shall be entitled to a [*] for additional development determined by the
Finance Committee, which shall not be less than [*] nor more than [*] of Net Sales of the Product in Territory B attributable to the New Indication or Line Extension. [*] shall be payable in accordance with Article 4 hereof (x) after the date
legal or de facto exclusivity of such Product would otherwise have ended until the date on which the legal or de facto exclusivity obtained as a result of the sole development terminates (whichever terminates first), in the case
referred to in clause (i) above, and (y) during the life of the relevant patent, in the case referred to in clause (ii) above. This [*] shall not exceed [*] of Net Sales of the Product in Territory B, even if the conditions in both
clauses (i) and (ii) above are satisfied, and shall not be reduced even if the Other Party exercises its right under Section 6.4 hereof to reverse its election not to participate in such development. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -10-

 6.6 Safety and Other Problems. Notwithstanding anything to the contrary in this
Article 6 or in Section 7.05(b) of the Alliance Support Agreement, if either Sanofi or BMS determines that the development of a New Indication or Line Extension should be suspended for a safety reason that it believes in good faith justifies
such suspension, or reasonably believes that such development would have a material adverse effect on the overall development of Clopidogrel, or the overall commercial viability of the resulting Product(s), such Party shall have the unilateral right
to veto the development by the other Party of such New Indication or Line Extension. 
 ARTICLE 7 

TERM; TERMINATION 
 7.1 Term; Termination. (a) The term of this Agreement shall commence on the date hereof and shall expire on December [*], 2019. Thereafter, the term of this Agreement may be renewed for
successive three-year terms by the mutual agreement of the Parties no later than 24 months prior to the expiration of the term then in effect. 
 (b) Notwithstanding the foregoing, this Agreement shall automatically expire upon the earlier of (i) the termination by both Parties of the commercialization of the Product in Territory B as the
result of a Safety Problem pursuant to Section 7.04(iii) of the Alliance Support Agreement and (ii) the exercise by BMS of the special put option pursuant to Section 7.08 of the Alliance Support Agreement. 

(c) The Parties may cause the early termination of this Agreement by the mutual written consent of each of the Parties. 

(d) Either Sanofi or BMS shall have the right to declare termination of this Agreement upon Notice to the other Parties, following the
first to occur of: 
 (i) such other Party shall have (A) voluntarily commenced any proceeding or filed any
petition seeking relief under Title 11 of the United States Code, Book VI of the French Commercial Code (legislative part as well as regulatory part) or any other bankruptcy, insolvency or similar law of the United States, any state thereof, the
French Republic or any other applicable jurisdiction, (B) applied for or consented to the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for all or substantially all of its
property, (C) filed an answer admitting the material allegations of a petition filed against or in respect of it in any such proceeding, (D) made a general assignment for the benefit of creditors of all or substantially all of its assets,
(E) become unable generally, or admitted in writing its inability to, pay all or substantially all of its debts as they become due or (F) taken corporate action for the purpose of effecting any of the foregoing; or 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -11-

 (ii) an involuntary proceeding shall have been commenced or any involuntary
petition shall have been filed in a court of competent jurisdiction seeking (A) relief in respect of such other Party, or of its property, under Title 11 of the United States Code, Book VI of the French Commercial Code (legislative part as well
as regulatory part) or any other bankruptcy, insolvency or similar law of the United States, any state thereof, the French Republic or any other applicable jurisdiction, (B) the appointment of a receiver, trustee, custodian, sequestrator,
conciliator, administrator or similar official for such other Party or for all or substantially all of its property or (C) the winding-up or liquidation of such other Party; and such proceeding or petition shall have continued undismissed for
sixty (60) days or an order or decree approving or ordering any of the foregoing shall have continued unstayed and in effect for thirty (30) days. 
 7.2 Consequences of Termination. (a) Upon the expiration or early termination of this Agreement pursuant to Section 7.1 hereof (the “License Termination Date”):

 (i) the terms and conditions of Section 7.07 of the Alliance Support Agreement shall apply, except in the
event of early termination pursuant to Section 7.1(b) hereof; 
 (ii) the Partnership shall cease, and shall
cause each sub-licensee (if any) to cease, all activities related to the Developed Know-How; and 
 (iii) the
Partnership shall pay in full all amounts due to Sanofi and/or BMS hereunder within ten (10) days after the final determination of Net Sales for such period, including the License Termination Date, pursuant to Sections 4.2, 4.3 and 4.5 hereof
which shall survive until the full payment of all amounts under this clause (iii). 
 (b) In the event of the termination of the
commercialization of the Products throughout Territory B pursuant to Section 7.04 of the Alliance Support Agreement (other than a bilateral termination of such Product as the result of a Safety Problem), the provisions of
Section 7.2(a)(ii)-(iii) hereof shall apply, mutatis mutandis, with respect to such Product. 
 (c) In the
event of the termination of the commercialization of the Products in any country of Territory B pursuant to Section 7.02 of the Alliance Support Agreement: 
 (i) the terms and conditions of Section 7.2(a)(ii)-(iii) hereof shall apply, mutatis mutandis, with respect to such country; and 

(ii) all rights and licenses granted by Sanofi and BMS hereunder with respect to such country shall revert to Sanofi and
BMS, respectively, subject to Section 7.03 of the Alliance Support Agreement. 
 (d) Expiration or early termination of
this Agreement pursuant to this Article 7 shall be without prejudice to any rights which shall have accrued to the benefit of any Party prior to such expiration or termination. Such expiration or termination shall not relieve any

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -12-

 
Party from its obligations which are expressly indicated to survive the expiration or termination of this Agreement. All of the Parties’ rights and obligations under this subclause
(d) and under Sections 4.4, 4.5, 4.6, 7.2 and 9.2 through 9.4 and Article 8 hereof shall survive such expiration or termination for the applicable period. 
 ARTICLE 8 
 CONFIDENTIALITY 

All of the data, material and information exchanged by the Parties hereunder or related hereto (including, without limitation, the
Developed Know-How) shall be subject to the confidentiality provisions of the Alliance Support Agreement as set forth in Section 5.03 thereof. 
 ARTICLE 9 
 MISCELLANEOUS 

9.1 Notices. All notices, requests or other communications hereunder (collectively, “Notices”) shall be in
writing, shall be in the English language, and shall be given or made by delivery in person, by courier service, by facsimile (with receipt confirmed) or by registered or certified mail (return receipt requested, with postage prepaid) to the
respective Parties at the following addresses: 
 If to Sanofi, to: 

Sanofi 
 54 rue
la Boétie 
 75008 Paris, France 
 Attention: Senior Vice President, Legal Affairs and General Counsel 
 Facsimile:
(33.1) 53.77.43.03 
 Attention: Vice President, Alliances & Partnerships 

Facsimile: (33.1) 53.77.40.99 
 with a copy to: 
 Weil Gotshal & Manges 

767 Fifth Avenue 
 New York NY 10153 
 Attention: [omitted] 

Facsimile: 212 310 8007 
 If to BMS, to: 
 Bristol-Myers Squibb Company 

P.O. Box 4000 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -13-

 
Route 206 & Province Line Road 
 Princeton, NJ 08543-4000 USA

 Attention: Vice President and Associate General Counsel, Transactional Practice Group 

Facsimile: (1-609) 252-7680 
 with a copy to: 
 Wilmer Cutler Pickering Hale and Dorr LLP 

7 World Trade Center 
 250 Greenwich Street 
 New York, NY 10007 USA 

Attention: [omitted] 
 Facsimile: (1-212) 230-8888 
 If to the Partnership, to: 

Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership 
 P.O. Box 4000 
 Route 206 & Province Line Road 

Princeton, NJ 08543-4000, USA 
 Attention: Vice President and Associate General Counsel, Transactional Practice Group 
 Facsimile: (1-609) 252-7680 
 with a copy to each of: 

sanofi-aventis U.S. LLC 
 55 Corporate Drive 
 Bridgewater, NJ 08807 USA 

Attention: [omitted] 
 Facsimile: (908) 981-5705 
 [omitted] 

General Counsel, North America 
 sanofi-aventis U.S. LLC 
 55 Corporate Drive 

Bridgewater, NJ 08807 
 Fax: (908) 981-7833 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -14-

 and: 
 Sanofi 
 54 rue la Boétie 

75008 Paris, France 
 Attention: Senior Vice President, Legal Affairs and General Counsel 
 Facsimile:
(33.1) 53.77.43.03 
 Attention: Vice President, Alliances & Partnerships 

Facsimile: (33.1) 53.77.40.99 

or to such other address or facsimile number as hereafter shall be furnished as provided in this Section 9.1 by any Party hereto to the other
Parties hereto. All Notices given to any Party in accordance with this Section 9.1 shall be deemed to have been given on the date of receipt if delivered by hand or overnight courier service or sent by facsimile, or on the date ten
(10) business days after dispatch by certified or registered mail (postage prepaid) if mailed. 
 9.2 Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of New York, United States of America, without regard to the choice of law principles that might otherwise be applied in such jurisdiction. 

9.3 Dispute Resolution. 
 (a) Negotiation and Notice. In the event of any dispute, claim, controversy or disagreement (each, a “Dispute”) arising out of, in connection with or relating to this Agreement
including any question regarding this Agreement’s existence, validity or termination, the Parties shall first seek resolution of such Dispute by negotiation between their respective senior management. Such negotiation shall be deemed to
commence upon the service by either Sanofi or BMS upon the other of a written notice (a “Dispute Resolution Notice”) under this Section 9.3(a). 
 (b) If a Dispute subject to negotiation under Section 9.3(a) is not finally resolved within thirty (30) days following receipt by either Sanofi or BMS of a Dispute Resolution Notice, the
Dispute shall be finally resolved by arbitration under the Rules of Arbitration of the International Chamber of Commerce (the “ICC”). The arbitral tribunal shall be composed of three (3) arbitrators. Each of Sanofi and BMS
shall nominate one (1) arbitrator. The two (2) arbitrators so nominated shall nominate the presiding arbitrator. If either Sanofi or BMS fails to nominate an arbitrator in its Request for Arbitration or within thirty (30) days of
receiving written notice of the nomination of an arbitrator by the other Party, such arbitrator shall be appointed by the ICC Court. If the two (2) arbitrators to be nominated by Sanofi and BMS fail to agree upon a third arbitrator within
thirty (30) days of the nomination of the second arbitrator, the third arbitrator shall be appointed by the ICC Court. The place of arbitration shall 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -15-

 
be Paris, France and the language of the arbitration shall be English. Notwithstanding any provision to the contrary in the ICC Rules of Arbitration, each Party shall bear its own costs and
expenses relating to such arbitration and all related proceedings, including fees for legal representation. Each Party shall continue to perform its respective obligations under this Agreement and this Agreement shall remain in effect while the
Dispute is being resolved. The Parties agree that any dispute arising out of or relating to this Agreement, the Definitive Agreement, or the Settlement Agreement (including the China Opt-Out Letter) or any Alliance Agreement (as such terms are
defined in the Definitive Agreement) shall be resolved in a single arbitration before the ICC, regardless of how many parties or agreements are implicated, and specifically waive any argument that a dispute arising out of or relating to this
Agreement shall be resolved in multiple arbitrations before the ICC. 
 9.4 Specific Performance. 

(a) Each Party agrees that the Developed Know-How is unique, and each Party hereby acknowledges and agrees that it and the other Party
would be damaged irreparably if any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached. Accordingly, each Party shall be entitled to seek specific performance and/or interim
relief, and agrees that the arbitral tribunal constituted under Section 9.3(b) shall have the power to order specific performance or grant provisional, interim, or conservatory measures, including but not limited to provisional injunctive
relief. The Parties undertake to comply forthwith with any such provisional, interim, or conservatory measures ordered by the arbitral tribunal and agree that such measures may, to the extent not precluded by applicable law, be enforceable as a
final award in any court of competent jurisdiction. For the avoidance of doubt, nothing in this provision shall prevent any Party from seeking conservatory or interim measures, including, but not limited to, temporary restraining orders or
preliminary injunctions or their equivalent, from any court of competent jurisdiction before the arbitral tribunal is constituted under Section 9.3(b) or, thereafter, upon the order of the arbitral tribunal. 

9.5 No Third Party Beneficiaries. This Agreement shall be binding upon and inure solely to the benefit of the Parties (including
the partners of the Partnership, each in its capacity as partner thereof) and permitted sub-licensees and assigns, and nothing herein, express or implied, is intended to, or shall confer upon, any other Person any legal or equitable right, benefit
or remedy of any nature whatsoever. 
 9.6 Assignment. 

(a) This Agreement may be assigned by a Party only to an Affiliate of Sanofi or BMS in the event of a corporate reorganization (including
an entity that becomes an Affiliate in connection with such reorganization) involving the assumption of all or substantially all of such Party’s marketing functions in Territory B by such Affiliate, in which event the rights may be assigned and
the obligations may be delegated to such Affiliate. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -16-

 (b) Notwithstanding anything to the contrary contained in subclause (a) above, this
Agreement may be assigned, in whole or in part, by, or on behalf of, the Partnership as a result of a termination event under either Section 7.04 or Section 7.06 of the Alliance Support Agreement or as a result of the dissolution of the
Partnership (other than for a Safety Problem) and in any such event shall be deemed to be amended and restated (i) to delete Sections 2.4, 2.5, 3.2 and 5.1-5.5 and Articles 6 and 8 hereof, as well as any reference to the Alliance Support
Agreement and (ii) to insert those terms and conditions that are then customary in the pharmaceutical industry for an intellectual property license agreement, including, without limitation, provisions for confidentiality, indemnification and
termination for material breach, as well as a diligence requirement that the assignee shall use reasonable commercial efforts to actively promote the Product(s) assigned (and the remedy for breach of such diligence requirement shall be termination
of such amended and restated agreement). 
 9.7 Severability. If any term or other provision hereof is held to be
invalid, illegal or incapable of being enforced by applicable law or public policy, all other terms and provisions hereof shall nevertheless remain in full force and effect so long as the economic effect or legal substance of the transactions
contemplated hereby is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. 

9.8 Waivers and Amendments. No modification of or amendment to this Agreement shall be valid unless in a writing signed by the
Parties referring specifically to this Agreement and stating the Parties’ intention to modify or amend the same. Any waiver of any term or condition of this Agreement shall be in a writing signed by the Party sought to be charged with such
waiver referring specifically to the term or condition to be waived, and no such waiver shall be deemed to constitute the waiver of any other breach of the same or of any other provision hereof. 

9.9 Headings. All titles and captions contained in this Agreement are for the convenience of reference only and shall not affect
in any way the meaning or interpretation hereof. 
 9.10 Entire Agreement. This Agreement and the Alliance Support
Agreement constitute the entire agreement of the Parties with respect to the subject matter contained herein and all prior agreements relative thereto which are not contained herein are hereby terminated. 

9.11 No Partnership or Joint Venture. This Agreement is not intended to create, and nothing contained herein shall be construed to
create an association, joint venture, trust or partnership, or to impose a trust or partnership covenant, obligation or liability on or with regard to the other Party. Each Party shall be severally responsible for its own covenants, obligations and
liabilities as herein provided. Other than the Partnership: (i) no Party shall be under the control of, or shall be deemed to control any other Party; (ii) no Party is the legal representative, agent, joint venturer or employee of the
other Party with respect to this Agreement for any purpose whatsoever, and no Party shall have the right or power to bind the 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -17-

 
other Party; and (iii) no Party has the right or authority to assume or create any obligations of any kind or to make any representation or warranty on behalf of any other Party, whether
express or implied, or to bind any other Party in any respect whatsoever. The provisions of this Agreement are intended only for the regulation of relations between the Parties. This Agreement is not intended for the benefit of non-Party creditors,
and no rights are granted to non-Party creditors under this Agreement. 
 9.12 Governing Language. The Parties
acknowledge that this Agreement may be translated into the French language. The Parties agree that this English language version shall in all respects be the controlling version of this Agreement. 

9.13 Counterparts. This Agreement may be executed in one or more counterparts, each of which when executed shall be deemed to be
an original, but all of which when taken together shall constitute one and the same agreement. 
 [Remainder of Page
Intentionally Left Blank] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 -18-

 IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the day and year
first written above. 
  

									
	SANOFI	 		 	 BRISTOL-MYERS SQUIBB SANOFI PHARMACEUTICALS HOLDING
 PARTNERSHIP

					
	By:	 	 /s/ T. Saugier
	 		 		 	
		 	 Name: T. Saugier
 Title:
Authorized representative
	 		 	Represented by:
			
	BRISTOL-MYERS SQUIBB COMPANY	 		 	BRISTOL-MYERS SQUIBB INVESTCO, L.L.C.
					
	By:	 	 /s/ Katherine Kelly
	 		 	By:	 	 /s/ Katherine Kelly

		 	 Name: Katherine Kelly
 Title:
Assistant Secretary
	 		 		 	 Name: Katherine Kelly
 Title:
Secretary

				
		 		 		 	Witnessed by:
				
		 		 		 	SANOFI-AVENTIS U.S. LLC
					
		 		 		 	By:	 	 /s/ T. Saugier

		 		 		 		 	 Name: T. Saugier
 Title:
Authorized representative

 [Signature Page to Amended and Restated Territory B Know-How License] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]